BC Innovations | Apr 11, 2013
Cover Story

RET, set, go

Just 15 months after Ret proto-oncogene fusions were first identified in 1%-2% of non-small cell lung cancer cases, early data from a Phase II trial of Exelixis Inc. 's Cometriq cabozantinib suggest that blocking the...
BC Innovations | Mar 1, 2012
Cover Story

REThinking lung cancer

Less than five years after the discovery of the EML4-ALK oncogenic fusion protein as a driver of non-small cell lung cancers, and less than a year after the FDA approved Pfizer Inc. 's Xalkori crizotinib...
Items per page:
1 - 2 of 2